Despite breakthrough science and innovative procedures, cardiovascular disease is rife with evidence-based racial disparities. Adopting quality initiatives, raising awareness, and inciting discussions about unconscious bias are recommended steps intended to narrow cardiovascular disease disparities. Progress is noted but a new challenge emerges. The implementation of transcatheter aortic valve replacement (TAVR), a life-sustaining technology, appears to mirror past patterns of race-based disparities. Has there been no real progress?